Literature DB >> 2171643

A specific inhibitor of the ubiquitin activating enzyme: synthesis and characterization of adenosyl-phospho-ubiquitinol, a nonhydrolyzable ubiquitin adenylate analogue.

K D Wilkinson1, S E Smith, L O'Connor, E Sternberg, J J Taggart, D A Berges, T Butt.   

Abstract

A nonhydrolyzable analogue of ubiquitin adenylate has been synthesized for use as a specific inhibitor of the ubiquitination of proteins. Ubiquitin adenylate is a tightly bound intermediate formed by the ubiquitin activating enzyme. The inhibitor adenosyl-phospho-ubiquitinol (APU) is the phosphodiester of adenosine and the C-terminal alcohol derived from ubiquitin. APU is isosteric with the normal reaction intermediate, the mixed anhydride of ubiquitin and AMP, but results from the replacement of the carbonyl oxygen of Gly76 with a methylene group. This stable analogue would be expected to bind to both ubiquitin and adenosine subsites and result in a tightly bound competitive inhibitor of ubiquitin activation. APU inhibits the ATP-PPi exchange reaction catalyzed by the purified ubiquitin activating enzyme in a manner competitive with ATP (Ki = 50 nM) and noncompetitive with ubiquitin (Ki = 35 nM). AMP has no effect on the inhibition, confirming that the inhibitor binds to the free form of the enzyme and not the thiol ester form. This inhibition constant is 10-fold lower than the dissociation constants for each substrate and 30-1000-fold lower than the respective Km values for ubiquitin and ATP. APU also effectively inhibits conjugation of ubiquitin to endogenous proteins catalyzed by reticulocyte fraction II with an apparent Ki of 0.75 microM. This weaker inhibition is consistent with the fact that activation of ubiquitin is not rate limiting in the conjugation reactions catalyzed by fraction II. APU is similarly effective as an inhibitor of the ubiquitin-dependent proteolysis of beta-lactoglobulin.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2171643     DOI: 10.1021/bi00484a004

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14.

Authors:  A Borodovsky; B M Kessler; R Casagrande; H S Overkleeft; K D Wilkinson; H L Ploegh
Journal:  EMBO J       Date:  2001-09-17       Impact factor: 11.598

Review 2.  Twists and turns in ubiquitin-like protein conjugation cascades.

Authors:  Brenda A Schulman
Journal:  Protein Sci       Date:  2011-11-09       Impact factor: 6.725

3.  Structural biology: Transformative encounters.

Authors:  Brenda A Schulman; Arthur L Haas
Journal:  Nature       Date:  2010-02-18       Impact factor: 49.962

4.  Uncoupling of p97 ATPase activity has a dominant negative effect on protein extraction.

Authors:  Halley B Rycenga; Kelly B Wolfe; Elizabeth S Yeh; David T Long
Journal:  Sci Rep       Date:  2019-07-17       Impact factor: 4.379

5.  Structural basis for adenylation and thioester bond formation in the ubiquitin E1.

Authors:  Zachary S Hann; Cheng Ji; Shaun K Olsen; Xuequan Lu; Michaelyn C Lux; Derek S Tan; Christopher D Lima
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 12.779

Review 6.  Anticancer drug discovery by targeting cullin neddylation.

Authors:  Qing Yu; Yihan Jiang; Yi Sun
Journal:  Acta Pharm Sin B       Date:  2019-09-20       Impact factor: 11.413

Review 7.  Ubiquitination and the Proteasome as Drug Targets in Trypanosomatid Diseases.

Authors:  Marie-José Bijlmakers
Journal:  Front Chem       Date:  2021-01-28       Impact factor: 5.221

Review 8.  Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways.

Authors:  Brenda A Schulman; J Wade Harper
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04-08       Impact factor: 94.444

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.